Despite the pharma's recent sea change in approach to drug discovery and development, U.S. pharmaceutical sciences graduate programs are currently maintaining a traditional methods for master's and doctoral student education. The literature on graduate education in the biomedical sciences has long been advocating educating students to hone soft skills like communication and teamwork, in addition to maintaining excellent basic skills in research. However, recommendations to date have not taken into account the future trends in the pharmaceutical industry. The AACP Graduate Education Special Interest Group has done a literature survey of the trends in the pharmaceutical industry and graduate education in order to determine whether our graduate programs are strategically positioned to prepare our graduates for successful careers in the next few decades. We recommend that our pharmaceutical sciences graduate programs take a proactive and leadership role in meeting the needs of our future graduates and employers. Our graduate programs should bring to education the innovation and collaboration that our industry also requires to be successful and relevant in this century.
The Committee created a SWOT (strengths, weaknesses, opportunities, and threat) analysis using this data, and identified priority recommendations:
• Support dual degree programs the SIG and to work with AACP in their planning process in the area of graduate education. To this end, the GEPC has studied the RGAC Report (2010-2011) and others, but also the literature pertaining to trends in pharmaceutical research and graduate education to inform our recommendations of how the future of our discipline might impact the strategic course for strengthening graduate education across all AACP and its member schools.
PHARMACEUTICAL INDUSTRY TODAY
Pharmacy faculty hear anecdotal information that the pharmaceutical industry has been undergoing significant change but few academics have direct and broad-based knowledge of its future trends.
A recent analysis from PricewaterhouseCoopers entitled "Pharma 2020:Virtual R&D -Which Path Will You Take" 2 explored current trends and the future of the pharmaceutical industry. The article described current trends in the industry to include:
• Declining productivity in research and development , more international and domestic outsourcing of activities to contract research organizations (CROs) 4, 13, 14 , and increased regulation 3, 5, 7 . Research and development in pharma is becoming more streamlined, thus many more graduates in the future will be working in small companies where the responsibilities are integrated 6, 15 .
In a recent Economist summit on pharma, Chief Strategy Officer for GlaxoSmithKline In addition to examining current trends, PWC also made several recommendations for the industry regarding the research areas that are becoming increasingly important 1for the industry:
• Need better virtual predictive models and simulation programs, including virtual organs, animal and human models to discover and test new drugs This new field has been increasingly used as a statistical tool involving probability theory to model outcomes, and to estimate risk/benefit for decision making in drug development 23 . Multiscale systems models, such as those that might include biology/physiology/pharmacology/pathophysicology elements concurrently, are also more commonly used to predict clinical success with experimental data. Multiscale models have already been applied to areas such as cardiovascular, diabetes, and . Recently, the NIH published a white paper 24 recommending support for quantitative systems pharmacology (QSP) to aid in developing precision medicines through a combination of computational and experimental research.
In summary, many of these emerging research areas have been designed to improve prediction of drug safety, clinical efficacy or cost-effectiveness at lower cost and more efficiently. Predictive sciences, including database management, biostatistics, programming and modeling are likely to become increasingly important components of drug discovery and development as a means to offset rising costs and lengthy studies.
Other PWC recommendations were made regarding the business practices of pharma:
• Encourage innovation based on individual performance, not candidate drug fate
• Develop and use clinical trial supercenters instead of decentralized multi-center trials facilitated by electronic data interchange and electronic records using common data formats
• Industry must work more closely with regulators and be willing to adapt based on their input
• Drug companies must decide whether to focus on mass market versus specialty medicines, outsource versus in-house R&D; this decision will affect the mix of skills needed in the workforce
• Change the way staff are remunerated and rewarded
• Be more innovative, collaborative/inclusive and cost-effective
The need to be more interdisciplinary and innovative has by necessity resulted in novel ways for pharma to collaborate with each other and academia. For example, open 10 innovation models have allowed shared risk and cost between collaborators that has been enabled by shared data and intellectual property 4, 14, 25, 26 another mechanism by which industry has been trying to become more competitive.
Several have stressed that underlying the new collaborative models and all else must be quality science 10 .
The future as described above will require graduates with additional skills beyond those taught in the lab. To be successful and to thrive with this dynamic landscape will require a range of skills in business, communication, teamwork, and leadership, among others (Table 1) . . In addition, the NIH funding mechanism has been inherently unstable and has perpetuated an overproduction of scientists 36 .
However, faculty have no control over the job market, so the traditional educational approach has been failing to prepare the remaining 86% of our graduates who enter non-academic careers 33 . Others have gone further to say that the academia has lacked both efficiency and interdisciplinarity 31 , both important characteristics that are needed to create a viable future for the pharmaceutical sciences and industry 30 .
The current funding mechanism for many of academic pharmaceutical scientists perpetuates the NIH-emphasized research. The large overhead funds that accompany NIH grants provides resources to the institution. Federal grants in general bring prestige to the institution. In addition, students often choose their research mentors based on their NIH-funding success. For these reasons, schools have many incentives to continue the current funding model.
Other threats to our graduate programs that have been identified include foreign graduate programs providing competition, releasing into a crowded and uncertain marketplace more graduates of mixed quality 18, 28 , decreased funding for graduate programs, insufficient advocacy by faculty for our graduate programs, and decreasing number of faculty with Pharmacy backgrounds 18 .
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GRADUATE PROGRAMS OF THE FUTURE
Pharmaceutical sciences graduate programs are now facing a potential crisis in terms of being able to sustain viable, yet relevant, graduate programs that produce scientists who are ready to contribute in academia, industry or non-research areas in our rapidly changing environment. The Academy should have as a primary goal to make our graduate programs more relevant for the graduates and all employers of the future.
To fully inform a strategic path to secure the relevance of our field, our discipline requires a needs analysis: our graduate programs should be responsive to current and future job needs, both in academia, industry and non-research positions 18, 28 . This analysis also requires we determine whether we are graduating an appropriate or excess number of doctoral or masters students for the market 18,28,31 and whether our graduates have the knowledge, skills and attitudes to be competitive for the jobs of the future or even lead the way into the new era of drug discovery and development. In this era of diminishing resources for higher education and basic research, how can an organization like AACP help meet the rapidly changing needs of the discipline? It is essential that AACP provide the leadership and support to enable the creation of a new future for our graduate programs. Indeed, for the creation and provision of high quality courses and degree programs in newly emerging areas, the time and resources needed to create the necessary core of faculty expertise can take years or decades for a given institution if acting alone. However, if one removes institutional and distance barriers to new program development, the speed, cost minimization and quality of program creation can be greatly enhanced.
Our programs must apply innovation and technology to enable both educational quality and efficiency simultaneously. In addition, the traditional silo and classroom approaches to graduate education are hindering our ability to be efficient and responsive to the needs of our profession. Efforts to increase professionalism, soft skills, and enhance career development also need not be repeatedly replicated within each School of Pharmacy. Shared workshops, courses and webinars could be offered 15 15 through AACP or collaboratively between a network of Schools to avoid repeatedly having to develop and teach programs to a small number of students.
New strategies to effectively train students for the future include collaborative education models (McCook, Sanders). Such collaborations typically occur between academic institutions but partnerships with industry and government can also provide mutual benefit in terms of increasing the pool of available expertise, and focus on topics and approaches that are relevant to employers. For example, the NIH Biomedical Workforce 29 suggest industrial partnerships and fellowships could be used to train students in nonacademic careers.
Collaborative models may be designed where some subjects are outsourced to other institutions, and/or certain faculty are shared between institutions. Online technology could be a useful tool to facilitate such collaborations, though online education seems to be slow to permeate graduate programs. Sanders 38 provides a model for online graduate education using an inter-institutional collaborative model for distance education.
The feasibility of such an approach has already been demonstrated by NIPTE (National Institute for Pharmaceutical Technology and Education; nipte.org) which offers training programs in pharmaceutical technology by using a network of collaborative schools who participate in teaching the course. Such a collaborative efforts could potentially address the concern of some faculty that soft skill development is a low priority, if such programs can be offered efficiently and for low cost. . The continued development of such open innovation models is necessary to sustain the highly innovative collaborative structures between industry and academia. So, it is imperative that future graduate programs understand these differences and develop relationships with industry that provide opportunities for investigators and companies to pursue research interests and goals that naturally overlap.
RECOMMENDATIONS
Because the future of the pharmaceutical sciences is changing and has changed so dramatically in recent years, strong leadership will be required to steer the Academy through a period of transition. Asking Schools to organize this transition at the grass roots level will result in delays and inefficiencies.
Therefore, we concur with the RGAC 2010-2011 report that AACP should take a central role in leading this effort at the national level, calling upon participation by Schools across the membership. Centralized, organizational leadership will not only be needed for new curriculum identification, creation, sharing, and offering, but also to help identify and secure funding for initiatives, survey research, creation of partnerships with stakeholders, creation of faculty and institutional development for the transition, best practices for intellectual property generated by these innovative collaborations, and assistance with the cultural change that will be needed to realize these changes, not only in the graduate programs but the Schools themselves.
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The consequences of inaction could lead to an increasing irrelevance of the pharmaceutical sciences to any place other than academia. The benefit of retooling our graduate programs can potentially be to revitalize and energize our students and alumni to find and create jobs that continue to make a meaningful contribution in health care.
Curriculum
• Create a Task Force (with input from stakeholders) to determine the need for specific core and specialty curriculum that will involve Schools across the • Foster research in emerging areas by offering small grants, recognition for excellence in the fields, and graduate student support*
• Facilitate fundraising for these new programs and curriculum by coordinating grants to NSF, advocacy and fundraising from stakeholders
• Increase the number and amount of new investigator funding available, especially in emerging disciplines
• Encourage schools to prioritize new faculty hires in emerging areas*
• Foster open innovation models between academia and pharma.
Development
• Provide and/ or organize student development programs via online or national/regional courses or workshops at low cost to programs and students*
• Develop faculty to enable the effective creation and implementation of emerging disciplines by providing exposure to and collaborative opportunities with scientists currently working in those disciplines, as well as protected time to pursue these new areas*
• Create a central location for advertising student internships; foster the creation of internships for pharmaceutical science graduate students in scientific and nonscientific areas
• Include in graduate training exposure to alternative career opportunities (i.e. scientific writing, patent law, leadership, financial management, etc.)*
Recruitment/Admissions/Pipeline
• Create tools (videos, website content, national effort to promote graduate education, centralized application process, etc.) for schools to use for recruitment and admission of applicants into graduate programs, especially
PharmD students
• Create scholarships specifically for PharmD students entering graduate school*
• Consider revising or expanding the graduate program admissions criteria to include key skills assessment *Indicates priority recommendations Implicit in this proposal is the need for the Academy to agree upon a shared vision for the future. Each school will have their own implementation needs and obstacles, so implementation will likely evolve in different ways to various endpoints for each institution. This agreement of the shared vision within the Academy and individual schools will be key to overcoming resistance to change. A realistic expectation should be maintained of the change timeline and amount of faculty time available for change. It is also neither realistic nor desirable to expect faculty to completely change their research or teaching areas; new areas of emphasis will likely begin and evolve as collaborations with existing scientists and so access to these scientists should be facilitated and encouraged.
In addition, the use of carrots rather than sticks is also more likely to be effective in encouraging change. For example, the recommendations include providing resources, recognition, access to experts, and leadership to enable the change.
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Without those critical elements, the faculty will likely and rightfully feel this evolution is yet another unfunded mandate. In contrast, with the right vision and leadership, the faculty may even take ownership of the change process in their institution, and find ways to creatively contribute and enhance the process for the Academy.
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